TPO-agonists for ITP
====================
Below is a forest plot of the *non-reponse* rates.
![Principle results](https://raw.githubusercontent.com/openMetaAnalysis/TPO-agonists-for-ITP/master/forest%20plots/TPO%20agonists%20for%20ITP.png "Principle results")

References:
----------------------------------
1. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011 PMID: <a href="http://pubmed.gov/20739054">20739054</a>. 
1. Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010 PMID: <a href="http://pubmed.gov/21067381">21067381</a>. 
1. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of eltrombopag on  platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 PMID: <a href="http://pubmed.gov/19231632">19231632</a>.
1. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefr√®re F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim  in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 PMID: <a href="http://pubmed.gov/18242413">18242413</a>. 

